Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug:102:118-121.
doi: 10.1016/j.ejim.2022.05.024. Epub 2022 May 25.

Efficacy and safety of molnupiravir for COVID-19 patients

Maurish Fatima  1 , Saleha Azeem  1 , Junaid Saeed  2 , Abia Shahid  1 , Huzaifa Ahmad Cheema  3 ; COVID-19 Therapeutics Study Group
Affiliations

Efficacy and safety of molnupiravir for COVID-19 patients

Maurish Fatima et al. Eur J Intern Med. 2022 Aug.
No abstract available

Keywords: COVID-19; EIDD-2801; MK-4482; Meta-analysis; Molnupiravir; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

The authors report no relationships that could be construed as a conflict of interest.

Figures

Fig 1
Fig. 1
Forest plot for the efficacy and safety of molnupiravir in randomized controlled trials. (A) 28–30 day mortality. (B) Hospitalization. (C) Mean reduction in viral load. (D) Virological clearance (negative PCR). (E) Adverse events. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
See this image and copyright information in PMC

References

    1. Tian L., Pang Z., Li M., Lou F., An X., Zhu S., et al. Molnupiravir and its antiviral activity against COVID-19. Front Immunol. 2022;13 - PMC - PubMed
    1. Dal-Ré R., Becker S.L., Bottieau E., Holm S. Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach. Lancet Infect Dis. 2022 doi: 10.1016/s1473-3099(22)00119-0. - DOI - PMC - PubMed
    1. Imran M., Kumar Arora M., Asdaq S.M.B., Khan S.A., Alaqel S.I., Alshammari M.K., et al. Discovery, development, and patent trends on molnupiravir: a prospective oral treatment for covid-19. Molecules. 2021;26 doi: 10.3390/molecules26195795. - DOI - PMC - PubMed
    1. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al., editors. Cochrane handbook for systematic reviews of interventions. 2nd ed. Wiley Blackwell; Hoboken, New Jersey: 2019. - DOI
    1. Arribas J.R., Bhagani S., Lobo S.M., Khaertynova I., Mateu L., Fishchuk R., et al. Randomized trial of molnupiravir or placebo in patients hospitalized with Covid-19. NEJM Evid. 2022;1 doi: 10.1056/EVIDoa2100044. - DOI - PubMed